MENTOR, Ohio -- STERIS Corporation today announced that the company, in cooperation with leading independent prion researchers, has participated in research that indicates the effectiveness of several of the company's proprietary cleaning and sterilization technologies in inactivating prions.
Prions are proteins that have been associated with debilitating and fatal illnesses in both animals and humans. Until now, it has not been possible to inactivate prions without damaging contaminated surfaces. STERIS has introduced a new consumableproduct in its healthcare segment, and is re-introducing an established consumable product in its life sciences segment to address prion concerns in both of its major industries.
This research has been published in the Aug. 7, 2004 edition of The
Lancet, an international journal of medical science and practice. Prions are
extremely difficult to inactivate from the surfaces of surgical instruments or
other items that may be contaminated and are believed to be the causative
agent of Transmissible Spongiform Encephalopathy (TSE), a group of fatal
animal and human diseases that affect the central nervous system. Examples of
such diseases in animals include scrapie and bovine spongiform
encephalopathies (BSE), which is commonly known as Mad Cow Disease. Human
variations include Creutzfeldt Jacob Disease (CJD) and variant Creutzfeldt
Jacob Disease (vCJD).
Commenting on the research, Les C. Vinney, STERIS's president and CEO, said, "We are pleased to have been involved in such
critically important research and to have our collaborative research
recognized by The Lancet. This research further confirms the value of our
technology portfolio and our belief that we can leverage our capabilities to
advance the science of sterilization and decontamination. STERIS continues to
provide cutting edge innovations to combat the latest and toughest infection
and decontamination challenges. We believe there are other opportunities
available to STERIS to commercialize additional new products to address the
impact of TSE's and we are continuing to pursue these opportunities."
As a result of this research, the company's healthcare segment has
introduced a new product in the United Kingdom. The product is a
cleansing solution designed to be added to the washing-disinfecting cycle of
washers that decontaminate surgical instruments after use, and will be sold
under the brand name Hamo 100 PID (Prion Inactivation Detergent). In
addition, the life sciences segment is re-introducing a cleaning solution
currently on the market that, as part of this research, has been proven to be
effective against prions. The product, CIP 100, is a leading solution used to
clean pharmaceutical and biotechnology production equipment. The company is
in the process of exploring additional commercialization opportunities for
this and other tested technologies.
In the process of its work with prions, STERIS also helped develop
standardized testing and validation protocols that were used to confirm the
validity of the test results. These validation protocols are being made
available to test the effectiveness of various other decontamination methods
against prions to advance research in these specialized areas.
Source: STERIS Corporation
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.